Prot#B3461045: A Phase 3 Multicenter, Open-Label Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826-83) 20 mg or 80 mg (or Tafamidis(06291826-00) 61 mg) in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)

Project: Research project

Project Details

Effective start/end date7/27/167/27/25


  • PPD Investigator Services, LLC (Prot #B3461045 // Prot #B3461045)
  • Pfizer Inc. (Prot #B3461045 // Prot #B3461045)